Abstract High-sensitivity C-reactive protein predicts future cardiovascular events in both healthy individuals and patients with unstable and stable coronary syndromes. Few data are available about the incidence and the relation to infl ammation of troponin elevation following percutaneous coronary intervention (PCI), a potential predictor of longterm outcome. We sought to confi rm the impact of embolization on long-term outcome and evaluate the ability of baseline infl ammation to predict troponin elevation induced by PCI. We prospectively analyzed 200 patients treated by PCI for stable or Braunwald IIA class unstable angina. The patients were recruited between January 1997 and May 1999, and the population was followed during a mean follow-up of 32 months. Major adverse cardiac events (MACEs) were defi ned as the occurrence of death, myocardial infarction or recurrent angina requiring repeat PCI, or coronary artery bypass grafting. During the follow-up period, 58 MACEs were observed. By multivariate analysis, independent predictors for the occurrence of MACEs were unstable angina and troponin I level after PCI (P < 0.0001 for both). No correlation was found between baseline infl ammation and signifi cant troponin I elevation post PCI and by multivariate analysis, no biological variable was a predictor of troponin I elevation post PCI. Baseline infl ammation cannot predict onset of minor myonecrosis damage (expressed by troponin elevation) induced by PCI, a significant predictor of long-term outcome in this setting.
Introduction
Among various studied infl ammatory markers, 1 high-sensitivity C-reactive protein is an infl ammatory marker that predicts future cardiovascular events in both healthy individuals with no history of cardiovascular disease and in patients with unstable as well as stable coronary syndromes. [2] [3] [4] [5] Preprocedural high-sensitivity C-reactive protein has been found to be an independent predictor of adverse cardiac events in patients treated by elective percutaneous coronary intervention (PCI) with or without a stent 6, 7 as well as in patients treated by surgical revascularization. 8 Infl ammatory reactivity has been found to be a powerful predictor of complication in stable angina treated by PCI. 9 Troponin elevation in the setting of elective intervention has been linked to higher mortality in several clinical settings. [10] [11] [12] Except for local anatomic characteristics 13 (i.e., side branch, degree of atheroma burden, evidence of thrombus in angiography), the predisposing factors that lead to periprocedural minor myonecrosis are not fully established. Especially, it is unknown if arterial infl ammation and heightened infl ammatory state could favor embolization and could be responsible for short-or long-term complications. Enhanced infl ammatory activity could be able to favor myocardial damage by various mechanisms (facilitating local recruitment of infl ammatory cells, altering small vessel function, destabilizing coronary plaque, promoting endothelial activation by a decreased nitric oxide bioavailability). Despite these different theoretical mechanisms, the inter-relationship between these two parameters is not fully understood. The purposes of this study were to evaluate the long-term prognostic impact of embolization in patients treated by PCI and afterward analyze the relation between baseline infl ammation and postprocedural troponin I elevation.
Patients and methods

Patients
Between January 1997 and May 1999, we prospectively analyzed 200 patients referred for coronary angioplasty for stable or Braunwald class IIa unstable angina. They underwent PCI of one or more coronary stenoses. The exclusion criteria were patients with suspected or confi rmed acute coronary syndrome (with or without ST segment elevation) at presentation or within 6 months, patients treated for restenosis, total occlusion or coronary graft, coronary artery bypass grafting, or PCI within 6 months, heart failure in New York Heart Association class ≥3, abnormal renal function, or known malignant or infl ammatory disorders. Follow-up was obtained in all patients by inspection of the medical records. Major adverse cardiac events (MACEs) were defi ned as the occurrence of death of any cause, myocardial infarction (with or without ST segment elevation), and any coronary revascularization (surgery and/or percutaneous). Myocardial infarction was defi ned as the occurrence of typical chest pain associated with an increase of creatine kinase-MB at least three times above the upper normal limit or with the development of new pathological Q waves on the electrocardiogram. All patients have given their informed consent and the study was approved by the local ethics committee.
Blood sampling
A fasting morning blood sample was taken from each patient on the day before and 24 h after the angioplasty. High-sensitivity C-reactive protein assays were measured by rate nephelometry using a commercially available kit (Behring N latex C-reactive protein mono Analyzer, Behring Diagnostic, Marburg, Germany). The lower detection limit was 0.175 mg/l. Troponin I assays were measured by a commercial microparticle enzyme immunoassay kit (AxSYM Abbott Laboratories, Abbott Park, IL, USA). The normal value is ≤0.5 μg/l (n = 437).
Coronary angiography
Selective coronary angiography was performed via the femoral route using a 6-F introducer sheath. Serial coronary angiograms of the left and right coronary arteries were performed after intracoronary administration of isosorbide dinitrate (0.2-0.4 mg). After diagnostic evaluation, angioplasty with or without stenting was performed. Heparin (70 U/kg) was given before the introduction of the guide wire. No patient received glycoprotein IIb/IIIa inhibitors, but all were pretreated with ticlopidine (500 mg) at least 4 h before intervention. All patients were treated with aspirin indefi nitely and ticlopidine 250 mg twice daily was added for 4 weeks in the patients treated by stenting.
Statistical analysis
Results are expressed as mean ± standard deviation (SD) for quantitative variables while frequencies and proportions (%) were used for categorical variables. Mean values were compared by the Student t-test (for normally distributed variables) and by the Wilcoxon test otherwise. Proportions were compared by the chi-squared test for contingency tables. Cox proportional hazards regression analysis was used to test the effect of covariates on major adverse cardiac event-free interval and to derive hazard ratio (HR) with 95% confi dence interval (95% CI). Multivariate logistic regression was used to detect clinical and/or biological predictor factors of signifi cant troponin I elevation. Odds ratio (OR) with 95% CI were also given. Results were considered signifi cant at the 5% critical level (P < 0.05). All calculations were performed using SAS (version 9.1 for Windows; SAS Institute, Cary, NC, USA) and S-PLUS (version 6.2; Insightful, Seattle, WA, USA) statistical packages.
Results
The clinical and biological characteristics of the studied population are listed in Table 1 . Mean baseline highsensitivity C-reactive protein levels were 4.21 ± 5.80 mg/l and were higher in smokers (4.29 ± 5.02 vs 4.06 ± 7.03 mg/l, P = 0.048) and in patients with unstable angina (5.42 ± 6.24 vs 4.06 ± 5.73 mg/l, P = 0.044). Baseline leukocyte count was higher in current smokers (7.74 ± 2.06 vs 6.89 ± 1.70 10 3 /mm 3 , P = 0.0018) while baseline fi brinogen was higher in diabetic patients (3.35 ± 0.80 vs 2.96 ± 0.70 g/l, P = 0.014). Values expressed as mean ± SD for age and as mean ± SEM for other values hsCRP, high-sensitivity C-reactive protein; PCI, percutaneous coronary intervention Mean baseline troponin I was 0.22 ± 0.61 μg/l, that it is to say within normal range (normal value ≤0.5 μg/l, n = 437) while post intervention mean values were 2.33 ± 6.7 μg/l. Patients treated with stent presented higher postintervention troponin I levels (3.58 ± 8.90 vs 1.01 ± 2.41 μg/l, P = 0.0002). Forty-four patients (22%) presented more than threefold elevation of troponin I after intervention. Those patients presented higher baseline troponin I levels (0.58 ± 1.02 vs 0.12 ± 0.37 μg/l, P < 0.0001) while their baseline C-reactive protein levels were higher but without reaching statistical signifi cance (5.85 ± 8.88 vs 3.76 ± 4.53 μg/l, P = 0.87).
During the follow-up period (mean = 30.8 ± 16.1 months), 29% of the studied population presented a major cardiac adverse event: 9 patients died, 12 patients presented acute myocardial infarction (2 Q-wave, 10 non-Q Wave), 5 patients underwent coronary artery bypass grafting for recurrent ischemia, 13 patients were treated by PCI on another lesion than the initial one, and 26 patients presented angiographic restenosis in whom 19 were treated by repeat PCI.
In multivariate analysis, the predictors of MACEs were unstable angina (HR: 6.58 [3.43-12.6] ) and troponin I post intervention (HR: 1.10 [1.05-1.15]) ( Table 2) . No relation was found between baseline high-sensitivity C-reactive protein levels and signifi cant elevation of troponin I induced by PCI (up to threefold the normal values). Neither was baseline C-reactive protein level correlated to delta troponin, defi ned as troponin I level post PCI minus troponin I pre PCI.
By multivariate analysis, the only predictor of signifi cant troponin I elevation post intervention was stent implantation (OR: 2.78 [1.18-6.56]). None of the studied biological parameters including especially baseline high sensitivity Creactive protein (P = 0.53) were predictors of troponin I elevation.
Discussion
In our study, as in previously published reports, we report a signifi cant prognostic impact of troponin I elevation after intervention on long-term outcome. 10,11,14,15. These troponin elevations may be in part closely related the procedure (embolization and/or closure of side branch). Unfortunately, even careful angiographic assessment cannot completely predict which patients will develop periprocedural embolization responsible for microvascular obstruction and necrosis. Moreover, detection of such a predisposing situation can only be made in the catheterization laboratory, ruling out the possibility of preinvasive optimal pharmacological preparation. Lesion morphology provides some prognostic information particularly in regard to the procedure-related risk but troponin is a more powerful predictor of cardiac risk than angiographic characteristics. 16 Nevertheless, underlying predisposing factors that lead to minor periprocedural myocardial infarction could also play a role. 17, 18 Systemic and arterial infl ammation favoring embolization is one of these potential predisposing factors that would be available prior to the catheterization laboratory. In this hypothesis, baseline C-reactive protein levels should be able to predict signifi cant troponin elevation post intervention. Contrary to Saadeddin et al., 19 we failed in this study to demonstrate this predictive ability of baseline infl ammation. In this previous report, which included a limited number of patients (n = 85), the authors used an arbitrary cutoff level of high-sensitivity C-reactive protein that was quite elevated (6 mg/l) to defi ne signifi cant enhanced infl ammation status.
Periprocedural myonecrosis predicts outcome although the exact threshold is undetermined, varying across studies. Therapies liable to reduce such minor necrosis also reduce long-term complications. [20] [21] [22] In the ARMYDA study 20 pretreatment with Atorvastatin, a drug with known antiinfl ammatory properties, 23 signifi cantly reduced procedural myocardial injury in an elective population but this effect was observed while C-reactive protein levels at the time of procedure were not signifi cantly different in the two groups. Periprocedural myonecrosis appears therefore as a target for therapy, and a preinvasive indicator of the susceptibility of subsequent event would be of great interest. In our report, baseline infl ammation does not demonstrate this property.
Stents usually lead to some degree of embolization, more frequently than does balloon angioplasty. 24 This observation is confi rmed in this study.
Study limitations
Although the data were collected prospectively, this is a retrospective single-center analysis and is subject to the limitations of such analysis. This study involves a limited population with a relatively short follow-up. No drug-eluting stents were used. Our observations are not necessarily applicable to other clinical settings. Platelet function was not evaluated and therefore it is impossible to exclude that some patients could present aspirin resistance, a factor known to promote periprocedural myonecrosis.
Conclusions
Periprocedural minor myocardial necrosis is a frequent observation in this study. The troponin release occurring after PCI is an independent predictive factor of outcome. The predisposing factors that lead to periprocedural minor myonecrosis are not fully established. In this study, baseline infl ammation assessed by high-sensitivity C-reactive protein measurement is not able to predict the occurrence of such troponin release corresponding to embolization.
